SEP-479 SAD/MAD data in Q1 2027 is the next major binary catalyst. The SEP-631 strategic pivot from a Phase 2b CSU study to signal-finding studies suggests a more cautious, capital-efficient approach — watch for clarity on study design and indications. The Novo Nordisk collaboration provides a steady revenue stream, but the stock remains a pipeline story. Cash runway into 2029 removes near-term financing risk.
Price Chart
Executive Summary
Septerna reported Q2 2026 financial results with a net loss of $13.0M, narrower than the $24.8M loss in Q2 2025. Revenue from the Novo Nordisk collaboration was $26.7M, and the company ended the quarter with $516.5M in cash, sufficient to fund operations into 2029. Key pipeline updates include the ongoing Phase 1 trial for SEP-479 (PTH1R agonist) with SAD/MAD data expected in Q1 2027, and a strategic shift for SEP-631 away from a Phase 2b CSU study toward capital-efficient signal-finding studies in mast cell-driven diseases.
Key Financial Metrics
Key Facts
- Net loss of $13.0M for Q2 2026 vs $24.8M for Q2 2025; revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex in Q2 2025.
- Cash position of $516.5M as of June 30, 2026, expected to fund operations at least into 2029.
- Phase 1 trial for SEP-479 (PTH1R agonist) ongoing; elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 strategic shift: company evaluating capital-efficient signal-finding studies in mast cell-driven diseases instead of the previously planned Phase 2b in CSU.
- TSHR NAM program progressing toward development candidate selection; Novo Nordisk collaboration advancing.
Financial Impact
No material financial impact; Q2 net loss $13.0M, revenue $26.7M, cash burn rate consistent with prior quarter.
Risk Factors
- SEP-479 Phase 1 data delay or negative safety/efficacy findings in Q1 2027.
- SEP-631 development uncertainty due to strategic reprioritization away from Phase 2b CSU.
- High R&D spend ($35.1M in Q2) may accelerate cash burn if pipeline timelines slip.
- Early-stage pipeline — no approved products; all value tied to clinical execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342328 |
| Document: sepn-20260810.htm | 0001193125-26-342328 |
| Document: 0001193125-26-342328-index-headers.html | 0001193125-26-342328 |
| Document: 0001193125-26-342328-index.html | 0001193125-26-342328 |
| Document: 0001193125-26-342328.txt | 0001193125-26-342328 |
| 8-K Data (Synthetic) | 0001193125-26-342328 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Press Release | $38.51 $38.69 | ▲ +0.47% | ▲ +0.69% | $38.27 (−0.62%) |
Sep 3, 2026 28d ago | 3 | $36.75 $39.55 | ▲ +7.62% | ▲ +8.83% | $38.27 (+4.14%) |
Aug 25, 2026 5w ago | 8-K | $41.30 $37.68 | ▼ −8.77% | ▼ −8.23% | $38.27 (−7.34%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 10, 2026 7w ago | 8-K | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Aug 10, 2026 7w ago | Press Release | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.00 $37.84 | ▲ +11.29% | ▲ +10.36% | $38.27 (+12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access